Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks

• DOI: 10.1080/09546634.2023.2263108
• Publication Date: 2023-10-02T09:40:49Z
• Authors: Alexander Egeberg; Lars Erik Kristensen; Luis Puig; Phoebe Rich; Saxon D. Smith; Alyssa Garrelts; Kyoungah See; Thorsten Holzkaemper; Konstantinos Fotiou; Christopher Schuster
• Keywords: Nail Psoriasis Severity Index (NAPSI); Nail psoriasis; Ixekizumab; Network Meta-Analysis; Dermatology; Biologics; Severity of Illness Index; physician’s global assessment of fingernails (pga-f); Nail Diseases; ixekizumab; Complete clearance/resolution of nail psoriasis; Adalimumab/therapeutic use; Psoriasis/drug therapy; Nail Diseases/drug therapy; Humans; Psoriasis; biologics; Network meta-analysis; network meta-analysis; Biological Products; Physician's Global Assessment of Fingernails (PGA-F); Adalimumab; Bayes Theorem; nail psoriasis; 3. Good health; Treatment Outcome; RL1-803; complete clearance/resolution of nail psoriasis; nail psoriasis severity index (napsi); Biological Products/therapeutic use

Available network meta-analyses (NMAs) comparing the efficacy of biologics in nail psoriasis (NP) have not included recently approved biologics such as bimekizumab nor have they provided comparisons up to 1 year. We conducted two NMAs that update and extend results from a previous NMA comparing biologics for achieving complete resolution of NP. Bayesian NMAs were performed using a generalized linear model with a logit link to model the binary outcome of nail clearance at weeks 24–28 and 48–52. For the NMA at weeks 24–28, which included seven biologics and placebo, the absolute probability of achieving complete resolution of NP was highest for ixekizumab (46.4%; 95% credibility interval [CrI] 35.2–58.0), followed by brodalumab (37.1%; 95% CrI 17.1–62.2) and bimekizumab (30.3%; 95% CrI 12.7–53.9). For the NMA at weeks 48–52, which included six biologics, the absolute probability was highest for ixekizumab (77.2%; 95% CrI 51.1–93.4), followed by adalimumab (75.6%; 95% CrI 61.5–87.3) and brodalumab (71.9%; 95% CrI 38.4–93.2). Among biologics included in these two NMAs, ixekizumab has the highest absolute probability of achieving complete resolution of NP. Results may help to inform treatment decisions for patients with NP.